Prot #HCRN MEL17-309/NU G18M02: Phase II Single-Arm Multi-Center Study of Adjuvant Ipilimumab in Combination with Nivolumab in Subjects with High-Risk Ocular Melanoma

Project: Research project

Project Details

StatusActive
Effective start/end date10/22/19 → 10/22/25

Funding

  • Hoosier Cancer Research Network, Inc. ((OE) Prot #HCRN MEL17-309/NU G18M02 // (OE) Prot #HCRN MEL17-...)
  • Bristol-Myers Squibb Company ((OE) Prot #HCRN MEL17-309/NU G18M02 // (OE) Prot #HCRN MEL17-...)